headerads

Monday, August 27, 2012

Celsion Jumps On Earnings (AMPE, HEB, CLSN, VLO, ACTG)


Ampio Pharmaceuticals Inc (NASDAQ:AMPE) went down 0.59% to $3.36 on a traded volume of 1.09 million shares. The stock opened at $3.47. The 52-week range of the stock $2.54 and $9.27.The Company has Price/Sales ratio of 2,857.58 and Price/Book ratio of 7.86. The 50-Day Moving Average and 200-Day Moving Average prices is $3.19 and $3.33 respectively. 

Hemispherx BioPharma Inc (NYSEAMEX: HEB) surged up 10.17% to $0.726.  The Company had filed on July 31, 2012 with the U.S. Food and Drug Administration complete response to the FDA's November 25, 2009 Complete Response Letter in support of Ampligen's New Drug Application for Chronic Fatigue Syndrome. The FDA acknowledged in writing receipt of the Company's August 1, 2012, response on August 10, 2012. Therefore, the user fee goal date is February 2, 2013.

Celsion Corporation (NASDAQ:CLSN) jumped up 8.97% to $5.10 on a traded volume of 1.46 million shares.  The Company reported second quarter net loss of $6.1 million or $0.18 per share compared to net loss of $6.9 million or $0.42 per share in the same period of 2011. Research and development costs were $4.1 million in the second quarter of 2012 compared to $5.0 million in the same period of 2011.

Can MKTS Continue To Move Higher? Find Out Here 

Valero Energy Corporation (NYSE:VLO) augmented 5.51% to $30.85 on a traded volume of 10.29 million shares. Simmons upgraded the rating on the stock to overweight in a report.
TheStreet Ratings restated buy with a ratings score of A- on the stock.

Acacia Research Corporation (NASDAQ:ACTG) climbed up 5.90% to $26.58. Advanced Data Access LLC and Smart Memory Solutions LLC, subsidiaries of Acacia Research Corporation entered into an agreement with Fujitsu Semiconductor America Inc and Fujitsu Semiconductor Limited. This agreement resolves patent litigation that was pending.

Acacia Research Corp announced that a subsidiary has acquired rights to patents for 360 degree view technology.  

No comments:

Post a Comment


Privacy Policy | Legal Disclaimer